Catalog No.
DHB95502
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa (DVD-Ig)
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
IL1F1, Interleukin-1 alpha, IL1A, Hematopoietin-1, IL-1 alpha, Interleukin-1 beta, IL1B, Catabolin, IL1F2, IL-1 beta
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01583 & P01584
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, ABT-981, CAS: 1791411-57-8
Clone ID
Lutikizumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis., PMID:30552176
A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis., PMID:30653843
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date., PMID:31916225
Osteoarthritis year in review 2019: epidemiology and therapy., PMID:31945457
Is Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis., PMID:33204726
Relative Efficacy and Safety of Anti-Inflammatory Biologic Agents for Osteoarthritis: A Conventional and Network Meta-Analysis., PMID:35887724
Does sex affect the efficacy of systemic pharmacological treatments of pain in knee osteoarthritis? A systematic review., PMID:38375468
Nonsurgical Knee Osteoarthritis Treatments for Reducing Inflammation as Measured on MRI Scans: A Systematic Review of Randomized Controlled Trials., PMID:39678436
Advances and Challenges in the Pursuit of Disease-Modifying Osteoarthritis Drugs: A Review of 2010-2024 Clinical Trials., PMID:40002768
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis, PMID: 30552176
Osteoarthritis year in review 2019: epidemiology and therapy, PMID: 31945457
Is Lutikizumab, an Anti-Interleukin-1 α/ β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis, PMID: 33204726
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date, PMID: 31916225
A Phase II Trial of Lutikizumab, an Anti-Interleukin-1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis, PMID: 30653843
For research use only. Not for human or drug use.
